• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国高死亡率地区 NSCLC 切除术病理报告的准确性和全面性趋势。

Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States.

机构信息

Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee.

Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee.

出版信息

J Thorac Oncol. 2021 Oct;16(10):1663-1671. doi: 10.1016/j.jtho.2021.06.027. Epub 2021 Jul 16.

DOI:10.1016/j.jtho.2021.06.027
PMID:34280563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9039869/
Abstract

INTRODUCTION

Complete and accurate pathology reports are vital to postoperative prognostication and management. We evaluated the impact of three interventions across a diverse group of hospitals on pathology reports of postresection NSCLC.

METHODS

We evaluated pathology reports for patients who underwent curative-intent surgical resection for NSCLC, at 11 institutions within four contiguous Dartmouth Hospital Referral Regions in Arkansas, Mississippi, and Tennessee from 2004 to 2020, for completeness and accuracy, before and after the following three quality improvement interventions: education (feedback to heighten awareness); synoptic reporting; and a lymph node specimen collection kit. We compared the proportion of pathology reports with the six most important items for postoperative management (specimen type, tumor size, histologic type, pathologic [p] T-category, pN-category, margin status) across the following six patient cohorts: preintervention control, postintervention with four different combinations of interventions, and a contemporaneous nonintervention external control.

RESULTS

In the postintervention era, the odds of reporting all key items were eight times higher than those in the preintervention era (OR = 8.3, 95 % confidence interval [CI]: 6.7-10.2, p < 0.0001). There were sixfold and eightfold increases in the odds of accurate pT- and pN-category reporting in the postintervention era compared with the preintervention era (pT OR = 5.7, 95 % CI: 4.7-6.9; pN OR = 8.0, 95 % CI: 6.5-10.0, both p < 0.0001). Within the intervention groups, the odds of reporting all six key items, accurate pT category, and accurate pN-category were highest in patients who received all three interventions.

CONCLUSIONS

Gaps in the quality of NSCLC pathologic reportage can be identified, quantified, and corrected by rationally designed interventions.

摘要

简介

完整且准确的病理学报告对于术后预后和管理至关重要。我们评估了在阿肯色州、密西西比州和田纳西州的四个达特茅斯医院转诊区的 11 家医院中,对多种类型的医院进行三种干预措施对手术后非小细胞肺癌(NSCLC)的病理学报告的影响。

方法

我们评估了 2004 年至 2020 年期间,在阿肯色州、密西西比州和田纳西州的四个连续的达特茅斯医院转诊区内的 11 家机构中,接受根治性手术切除的 NSCLC 患者的病理学报告,以评估其完整性和准确性。这些患者的报告在以下三种质量改进干预措施前后进行了比较:教育(反馈以提高认识);综合报告;以及淋巴结标本采集包。我们比较了以下六个患者队列中六个最重要的术后管理项目(标本类型、肿瘤大小、组织学类型、病理 [p] T 分期、pN 分期、切缘状态)的病理学报告比例:干预前对照、干预后有四种不同组合的干预、以及同时期的非干预外部对照。

结果

在干预后时期,报告所有关键项目的几率是干预前时期的八倍(OR = 8.3,95%置信区间 [CI]:6.7-10.2,p < 0.0001)。与干预前时期相比,在干预后时期,准确报告 pT 分期和 pN 分期的几率增加了六倍和八倍(pT OR = 5.7,95%CI:4.7-6.9;pN OR = 8.0,95%CI:6.5-10.0,均 p < 0.0001)。在干预组内,接受三种干预措施的患者报告所有六个关键项目、准确的 pT 分期和准确的 pN 分期的几率最高。

结论

通过合理设计的干预措施,可以确定、量化和纠正 NSCLC 病理报告质量方面的差距。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/9039869/e497e6f995d6/nihms-1725181-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/9039869/82484d2448d0/nihms-1725181-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/9039869/e497e6f995d6/nihms-1725181-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/9039869/82484d2448d0/nihms-1725181-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5382/9039869/e497e6f995d6/nihms-1725181-f0002.jpg

相似文献

1
Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States.美国高死亡率地区 NSCLC 切除术病理报告的准确性和全面性趋势。
J Thorac Oncol. 2021 Oct;16(10):1663-1671. doi: 10.1016/j.jtho.2021.06.027. Epub 2021 Jul 16.
2
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
3
Evolution in the Surgical Care of Patients With Non-Small Cell Lung Cancer in the Mid-South Quality of Surgical Resection Cohort.中南地区手术切除质量队列中非小细胞肺癌患者外科治疗的进展
Semin Thorac Cardiovasc Surg. 2017;29(1):91-101. doi: 10.1053/j.semtcvs.2016.10.001. Epub 2016 Oct 14.
4
Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort.基于人群的肺癌队列中直接手术质量反馈前后的生存情况。
Ann Thorac Surg. 2019 May;107(5):1487-1493. doi: 10.1016/j.athoracsur.2018.11.058. Epub 2018 Dec 27.
5
Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer.实施干预措施对非小细胞肺癌病理性淋巴结分期的效果。
Ann Thorac Surg. 2018 Jul;106(1):228-234. doi: 10.1016/j.athoracsur.2018.02.021. Epub 2018 Mar 11.
6
Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes.淋巴结采集套件与提高肺癌手术质量和结果的意识比较的有效性。
J Thorac Oncol. 2021 May;16(5):774-783. doi: 10.1016/j.jtho.2021.01.1618. Epub 2021 Feb 12.
7
Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.肺癌手术中使用淋巴结采集试剂盒后的结果:一项基于人群、多机构、交错实施的实用性研究
J Thorac Oncol. 2021 Apr;16(4):630-642. doi: 10.1016/j.jtho.2020.12.025. Epub 2021 Feb 16.
8
Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer.使用手术标本采集套件改善可切除肺癌的纵隔淋巴结检查。
J Thorac Oncol. 2012 Aug;7(8):1276-82. doi: 10.1097/JTO.0b013e318257fbe5.
9
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法(不包括检查点抑制剂)。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
10
Proposal of a new nodal classification for operable non-small cell lung cancer based on the number of negative lymph nodes and the anatomical location of metastatic lymph nodes.基于阴性淋巴结数量和转移性淋巴结解剖位置的可手术非小细胞肺癌新的淋巴结分类方案
Medicine (Baltimore). 2019 May;98(20):e15645. doi: 10.1097/MD.0000000000015645.

引用本文的文献

1
Two Interventions on Pathologic Nodal Staging in a Population-Based Lung Cancer Resection Cohort.两种干预措施对基于人群的肺癌切除队列中病理性淋巴结分期的影响。
Ann Thorac Surg. 2024 Mar;117(3):576-584. doi: 10.1016/j.athoracsur.2023.08.026. Epub 2023 Sep 5.
2
Surgical Treatment is Still Recommended for Patients Over 75 Years with IA NSCLC: A Predictive Model Based on Surveillance, Epidemiology and End Results Database.对于 75 岁以上的 IA NSCLC 患者,仍推荐进行手术治疗:基于监测、流行病学和最终结果数据库的预测模型。
Cancer Control. 2022 Jan-Dec;29:10732748221142750. doi: 10.1177/10732748221142750.
3
Overexpression of miR-328-5p influences cell growth and migration to promote NSCLC progression by targeting LOXL4.

本文引用的文献

1
Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis.淋巴结标本采集试剂盒对拟议的修订版肺癌残留疾病分类的分布及生存影响:一项倾向匹配分析
JTO Clin Res Rep. 2021 Mar 9;2(4):100161. doi: 10.1016/j.jtocrr.2021.100161. eCollection 2021 Apr.
2
Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.肺癌手术中使用淋巴结采集试剂盒后的结果:一项基于人群、多机构、交错实施的实用性研究
J Thorac Oncol. 2021 Apr;16(4):630-642. doi: 10.1016/j.jtho.2020.12.025. Epub 2021 Feb 16.
3
miR-328-5p的过表达通过靶向LOXL4影响细胞生长和迁移,从而促进非小细胞肺癌进展。
Ann Transl Med. 2022 Mar;10(6):301. doi: 10.21037/atm-22-345.
Cancer Statistics, 2021.
癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
4
Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer.实施干预措施对非小细胞肺癌病理性淋巴结分期的效果。
Ann Thorac Surg. 2018 Jul;106(1):228-234. doi: 10.1016/j.athoracsur.2018.02.021. Epub 2018 Mar 11.
5
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
6
Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States.根据美国非小细胞肺癌患者的切缘状态,术后治疗方式对生存的影响。
J Thorac Cardiovasc Surg. 2017 Aug;154(2):661-672.e10. doi: 10.1016/j.jtcvs.2017.03.085. Epub 2017 Apr 4.
7
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.Ⅰ期至ⅢA 期完全切除的非小细胞肺癌的辅助全身治疗和辅助放疗:美国临床肿瘤学会/安大略癌症护理临床实践指南更新。
J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24.
8
Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Criteria.美国国立综合癌症网络肺癌切除质量标准的预后价值
Ann Thorac Surg. 2017 May;103(5):1557-1565. doi: 10.1016/j.athoracsur.2017.01.098. Epub 2017 Mar 31.
9
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer.非小细胞肺癌切除术后肺内淋巴结转移漏诊与生存情况
Ann Thorac Surg. 2016 Aug;102(2):448-53. doi: 10.1016/j.athoracsur.2016.03.096. Epub 2016 Jun 3.
10
The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review.实施概要病理报告在癌症诊断中的效果:一项系统评价
Virchows Arch. 2016 Jun;468(6):639-49. doi: 10.1007/s00428-016-1935-8. Epub 2016 Apr 21.